Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-05T08:51:13.827Z Has data issue: false hasContentIssue false
  • English
  • Français

Isoflavone exposure throughout suckling results in improved adult bone health in mice

Published online by Cambridge University Press:  06 March 2012

E. C. Dinsdale ,
J. Kaludjerovic  and
W. E. Ward
E. C. Dinsdale
Affiliation:
Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
J. Kaludjerovic
Affiliation:
Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
W. E. Ward*
Affiliation:
Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada Center for Bone and Muscle Health, Faculty of Applied Health Sciences, Brock University, St Catharines, Ontario, Canada
*
*Address for correspondence: W. E. Ward, Department of Kinesiology, Faculty of Applied Health Sciences, Brock University, St Catharines, Ontario, Canada L2S 3A1. (Email [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Exposure to isoflavones (ISO), abundant in soy protein infant formula, for the first 5 days of life results in higher bone mineral density (BMD), greater trabecular connectivity and higher peak load of lumbar vertebrae (LV) at adulthood. The effect of lengthening the duration of exposure to ISO on bone development has not been studied. This study determined if providing ISO for the first 21 days of life, which more closely mimics the duration that infants are fed soy protein formula, results in higher BMD, improved bone structure and greater strength in femurs and LV than a 5-day protocol. Female CD-1 mice were randomized to subcutaneous injections of ISO (7 mg/kg body weight/day) or corn oil from postnatal day 1 to 21. BMD, structure and strength were measured at the femur and LV at 4 months of age, representing young adulthood. At the LV, exposure to ISO resulted in higher (P < 0.05) BMD, trabecular connectivity and peak load compared with control (CON). Exposure to ISO also resulted in higher (P < 0.05) whole femur BMD, higher (P < 0.05) bone volume/total volume and lower (P < 0.05) trabecular separation at the femur neck, as well as greater (P < 0.05) peak load at femur midpoint and femur neck compared with the CON group. Exposure to ISO throughout suckling has favorable effects on LV outcomes, and, unlike previous studies using 5-day exposure to ISO, femur outcomes are also improved. Duration of exposure should be considered when using the CD-1 mouse to model the effect of early life exposure of infants to ISO.

Keywords

bone developmentbone structureCD-1 mouse modelisoflavonesnutritional programming
Type
Original Article
Information
Journal of Developmental Origins of Health and Disease , Volume 3 , Issue 4 , August 2012 , pp. 271 - 275
Copyright
Copyright © Cambridge University Press and the International Society for Developmental Origins of Health and Disease 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

†

E. C. Dinsdale and J. Kaludjerovic share first authorship.

References

1.Piekarz, AV, Ward, WE. Effect of neonatal exposure to genistein on bone metabolism in mice at adulthood. Pediatr Res. 2007; 61, 48–53.CrossRefGoogle Scholar
2.Kaludjerovic, J, Ward, WE. Neonatal exposure to daidzein, genistein, or the combination modulates bone development in female CD-1 mice. J Nutr. 2009; 139, 467–473.CrossRefGoogle ScholarPubMed
3.Kaludjerovic, J, Ward, WE. Neonatal administration of isoflavones attenuates deterioration of bone tissue in female but not male mice. J Nutr. 2010; 140, 766–772.CrossRefGoogle Scholar
4.Bronikowski, AM, Carter, PA, Morgan, TJ, et al. . Lifelong voluntary exercise in the mouse prevents age-related alterations in gene expression in the heart. Physiol Genomics. 2003; 12, 129–138.CrossRefGoogle ScholarPubMed
5.Losel, RM, Falkenstein, E, Feuring, M, et al. . Nongenomic steroid action: controversies, questions, and answers. Physiol Res. 2003; 83, 965–1016.Google ScholarPubMed
6.Reeves, PG. Components of the AIN-93 diets as improvements in the AIN-76A diet. J Nutr. 1997; 127(Suppl 5), S838–S841.CrossRefGoogle ScholarPubMed
7.Setchell, KD, Zimmer-Nechemias, L, Cai, J, et al. . Isoflavone content of infant formulas and the metabolic fate of these phytoestrogens in early life. Am J Clin Nutr. 1998; 68(Suppl 6), S1453–S1461.CrossRefGoogle ScholarPubMed
8.Setchell, KDR, Zimmer-Nechemias, L, Cai, J, et al. . Exposure of infants to phyto-oestrogens from soy-based infant formula. Lancet. 1997; 350, 23–27.CrossRefGoogle ScholarPubMed
9.Ward, WE, Piekarz, AV, Fonseca, D. Bone mass, bone strength, and their relationship in developing CD-1 mice. Can J Physiol Pharmacol. 2007; 85, 274–279.CrossRefGoogle ScholarPubMed
10.Canadian Council on Animal Care. Guide to the Care and Use of Experimental Animals, 2nd edn, 1993. Canadian Council on Animal Care: Ottawa, ON, Canada, pp. 1–212.Google Scholar
11.Fonseca, D, Ward, WE. Daidzein together with high calcium preserve bone mass and biomechanical strength at multiple sites in ovariectomized mice. Bone. 2004; 35, 489–497.CrossRefGoogle ScholarPubMed
12.Eisman, JA, Kelly, PJ, Morrison, NA, et al. . Peak bone mass and osteoporosis prevention. Osteoporos Int. 1993; 3(Suppl. 1), 56–60.CrossRefGoogle ScholarPubMed
13.Johnston, CCJ, Slemender, CW. Risk prediction in osteoporosis: a theoretic overview. Am J Med. 1991(5B); 91, 47S–48S.CrossRefGoogle ScholarPubMed
14.Johnston, CCJ, Miller, JZ, Slemenda, CW, et al. . Calcium supplementation and increases in bone mineral density in children. N Engl J Med. 1992(5B); 327, 82–87.CrossRefGoogle ScholarPubMed
15.Chevalier, Y, Quek, E, Borah, B, et al. . Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body. Bone. 2010; 46, 41–48.CrossRefGoogle ScholarPubMed
16.Ensrud, KE, Schousboe, JT. Clinical practice: vertebral fractures. N Engl J Med. 2011; 364, 1634–1642.CrossRefGoogle ScholarPubMed
17.Newbold, RR, Padilla-Banks, E, Snyder, RJ, et al. . Developmental exposure to estrogenic compounds and obesity. Birth Defects Res A Clin Mol Teratol. 2005; 73, 478–480.CrossRefGoogle ScholarPubMed
18.Reinwald, S, Weaver, CM. Soy isoflavones and bone health: a double-edged sword? J Nat Prod. 2006; 69, 450–459.CrossRefGoogle Scholar
19.Dinsdale, EC, Ward, WE. Early exposure to soy isoflavones and effects on reproductive health: a review of human and animal studies. Nutrients. 2010; 2, 1156–1187.CrossRefGoogle ScholarPubMed
20.Unfer, V, Casini, ML, Costabile, L, et al. . Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2004; 82, 145–148.CrossRefGoogle ScholarPubMed
21.Kaludjerovic, J, Franke, AA, Ward, WE. Circulating isoflavonoid levels in CD-1 mice: effect of oral versus subcutaneous delivery and frequency of administration. J Nutr Biochem. 2011; June 8 [Epub ahead of print].Google ScholarPubMed
22.Klein, MA, Nahin, RL, Messina, MJ, et al. . Guidance from an NIH workshop on designing, implementing, and reporting clinical studies of soy interventions. J Nutr. 2010; 140, 1192S–1204S. [Epub April 14, 2010].CrossRefGoogle ScholarPubMed